News Bulletin
Thursday, January 08, 2026
Evening Edition

Economic Numbers:

Time

Event

Actual

Forecast

Previous

5:30

Challenger Job Cuts (YoY)

-8.30%

 

23.50%

7:30

Challenger Job Cuts (Dec)

35.553K

 

71.321K

8:30

Continuing Jobless Claims

1,914K

1,900K

1,858K

8:30

Exports (Oct)

302.00B

 

289.30B

8:30

Imports (Oct)

331.40B

 

342.10B

8:30

Initial Jobless Claims

208K

213K

200K

8:30

Jobless Claims 4-Week Avg.

211.75K

 

219.00K

8:30

Nonfarm Productivity (QoQ) (Q3) 

4.90%

4.90%

4.10%

8:30

Trade Balance (Oct)

-29.40B

-58.10B

-48.10B

8:30

Unit Labor Costs (QoQ) (Q3) 

-1.90%

0.00%

-2.90%

10:30

Natural Gas Storage

-119B

-109B

-38B

11:00

NY Fed 1-Year Consumer Inflation Expectations (Dec)

3.40%

 

3.20%

12:00

Atlanta Fed GDPNow (Q4) 

5.40%

2.70%

2.70%

15:00

Consumer Credit (Nov)

4.23B

10.10B

9.24B

Indices
 

 

CLOSE

50 DMA

200 DMA

DJIA

49,266.11

47,748.52

44,684.95

NASDAQ

23,480.02

23,281.69

20,970.73

S&P 500

6,921.46

6,816.70

6,317.25

Earnings Calendar:

(EPS: Earning Per Share / Rev: Revenue / Mkt Cap : market Capital/ BMO : Before Market Opening /AMC : After Market Close)

Company

EPS

  Forecast

Revenue

  Forecast

Market Cap

Time

Fast Retailing ADR (FRCOY)

--

0.2601

--

  6.31B

110.92B

BMO

Aeon ADR (AONNY)

--

0.009

--

  16.77B

41.7B

BMO

Tesco PLC (TSCDY)

--

  --

--

  22.93B

36.07B

BMO

Seven i ADR (SVNDY)

--

0.1966

--

  15.9B

34.01B

BMO

RPM (RPM)

1.2

1.43

1.91B

  1.94B

13.44B

BMO

TD Synnex (SNX)

3.83

3.73

17.38B

  16.93B

11.99B

BMO

Acuity Brands (AYI)

4.69

4.58

1.14B

  1.14B

11.28B

BMO

Commercial Metals (CMC)

1.84

1.56

2.12B

  2.06B

7.85B

BMO

Sodexo PK (SDXAY)

--

  --

7.3B

  --

7.38B

BMO

Simply Good Foods (SMPL)

0.39

0.36

340.2M

  335.93M

1.96B

BMO

Neogen (NEOG)

0.1

0.03

224.7M

  208.12M

1.6B

BMO

Lindsay (LNN)

1.54

1.53

155.8M

  172.42M

1.26B

BMO

Helen of Troy Ltd (HELE)

1.71

1.69

512.8M

  502.42M

478.54M

BMO

Northern Technologies (NTIC)

0.04

0.02

23.31M

  20.7M

83.05M

BMO

Marks & Spencer Group Plc (MAKSY)

--

  --

--

  --

9.33B

 

WaFd Inc (WAFD)

--

0.755

--

  192.83M

2.57B

 

Park Aerospace (PKE)

--

  --

--

  --

468.98M

 

Lifecore Biomedical (LFCR)

--

-0.16

--

  37.21M

292.24M

 

Hurco (HURC)

--

  --

--

  --

98.63M

 

Loop Industries (LOOP)

--

-0.055

--

  875K

52.85M

 

Brookmount Explorations Inc (BMXI)

--

  --

--

  --

12.27M

 

Educational Development (EDUC)

--

  --

--

  --

12.19M

 

WD-40 (WDFC)

1.28

1.45

154.4M

  161.2M

2.74B

AMC

Greenbrier (GBX)

1.14

0.87

--

  675.25M

1.66B

AMC

Aehr Test Systems (AEHR)

--

-0.0287

--

  12.42M

682.05M

AMC

Simulations Plus (SLP)

0.13

0.19

18.4M

  17.97M

361.63M

AMC

 

Market News:   

 

Here are some of the biggest premarket US stock movers today:

 

Toll Brothers Inc. (TOL) announced that Chairman and Chief Executive Officer Douglas C. Yearley Jr. will transition to Executive Chairman on March 30, 2026. Karl K. Mistry, Executive Vice President, will succeed Yearley as CEO and join the board of directors on the same date.

 

Jasper Therapeutics Inc. (JSPR) appointed Jeet Mahal as president and chief executive officer, effective January 5. Mahal succeeds Ronald Martell, who stepped down after serving as CEO since 2022.

 

Jefferies Financial Group Inc (NYSE:JEF) Inc reported fourth-quarter earnings that fell short of analyst expectations on Wednesday, despite posting strong investment banking revenue growth as dealmaking activity rebounded across Wall Street.

 

Lockheed Martin (LMT) delivered 191 F-35 Lightning II aircraft in 2025, exceeding the previous record of 142 jets, according to a company statement.

 

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) stock tumbled 11.7% in after-hours trading Wednesday after the gastrointestinal disease treatment developer announced plans for a public offering of common stock and pre-funded warrants.

 

Kura Sushi USA, Inc. (NASDAQ:KRUS) reported a wider-than-expected loss for its fiscal first quarter ended November 30, 2025, despite slightly exceeding revenue expectations.

 

Immuneering Corporation (IMRX) reported that 64% of first-line pancreatic cancer patients treated with its experimental drug atebimetinib combined with modified gemcitabine/nab-paclitaxel survived at 12 months in a Phase 2a clinical trial.

 

 

For internal use only